You are here

Experimental Drug Aids Patients With Hyperlipidemia

AMG 145 lowered lipoprotein(a) levels better than placebo (August 28)
As part of the LAPLACE–TIMI 57 trial, 631 patients with hypercholesterolemia who were receiving statins were randomly assigned to receive AMG 145 at one of three different doses every 2 weeks or one of three different doses every 4 weeks versus placebo. Lp(a) and other lipid parameters were measured at baseline and at week 12.

Compared with placebo, AMG 145 at doses of 70 mg, 105 mg, and 140 mg every 2 weeks reduced Lp(a) levels at 12 weeks by 18%, 32%, and 32%, respectively (P The effect of AMG 145 on Lp(a) levels was consistent regardless of patients’ age, sex, race, history of diabetes, and previous statin regimen. Patients with higher levels of Lp(a) at baseline had larger absolute reductions but comparatively smaller percentage reductions in Lp(a) with AMG 145 compared with patients who had lower baseline Lp(a) values.

In summary, AMG 145 significantly reduced Lp(a) by up to 32% in subjects with hypercholesterolemia who were receiving a statin.

Sources: Circulation 2013;128:962–969; ClinicalTrials.gov; and Amgen

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs